$1.01
-0.01 (-0.98%)
Open$1.04
Previous Close$1.02
Day High$1.04
Day Low$1.00
52W High$3.90
52W Low$1.00
Volume—
Avg Volume26.1K
Market Cap4.96M
P/E Ratio—
EPS$-2.03
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,538.6% upside
Current
$1.01
$1.01
Target
$16.55
$16.55
$10.07
$16.55 avg
$19.24
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 241.42M | 953.7K | 857.2K |
| Net Income | -35,540,980 | 90.7K | 81.5K |
| Profit Margin | -14.7% | 9.5% | 9.5% |
| EBITDA | -38,686,922 | 169.7K | 158.3K |
| Free Cash Flow | — | 104.6K | 58.4K |
| Rev Growth | +434.8% | +23.3% | +22.6% |
| Debt/Equity | — | 0.69 | 0.48 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |